MX2014002307A - Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis. - Google Patents

Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.

Info

Publication number
MX2014002307A
MX2014002307A MX2014002307A MX2014002307A MX2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A
Authority
MX
Mexico
Prior art keywords
hypertension associated
gene
angiogenesis
bevacizumab
genotype
Prior art date
Application number
MX2014002307A
Other languages
English (en)
Spanish (es)
Inventor
Sanne Lysbet De Haas
Paul Delmar
Diether Lambrechts
Stefan Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002307A publication Critical patent/MX2014002307A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
MX2014002307A 2011-08-31 2012-08-28 Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis. MX2014002307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11179500 2011-08-31
PCT/EP2012/066632 WO2013030168A1 (en) 2011-08-31 2012-08-28 Method for predicting risk of hypertension associated with anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
MX2014002307A true MX2014002307A (es) 2014-08-26

Family

ID=46724461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002307A MX2014002307A (es) 2011-08-31 2012-08-28 Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.

Country Status (16)

Country Link
US (1) US20140294811A1 (ja)
EP (2) EP2751280B1 (ja)
JP (1) JP2014526901A (ja)
KR (1) KR20140064924A (ja)
CN (1) CN103946395A (ja)
AR (1) AR087714A1 (ja)
AU (1) AU2012300986A1 (ja)
BR (1) BR112014004763A2 (ja)
CA (1) CA2845386A1 (ja)
ES (1) ES2589455T3 (ja)
IL (1) IL230783A0 (ja)
MX (1) MX2014002307A (ja)
RU (1) RU2014110270A (ja)
SG (1) SG2014008585A (ja)
WO (1) WO2013030168A1 (ja)
ZA (1) ZA201400950B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028448B2 (en) 2019-09-20 2021-06-08 The University Of North Carolina At Chapel Hill Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5604099A (en) 1986-03-13 1997-02-18 Hoffmann-La Roche Inc. Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5310893A (en) 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4851331A (en) 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
WO1989001050A1 (en) 1987-07-31 1989-02-09 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5137806A (en) 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69128520T2 (de) 1990-10-31 1998-07-09 Tosoh Corp Verfahren zum Nachweis oder Quantifizierung von Zielnukleinsäuren
IL100040A (en) 1990-11-13 1995-12-31 Siska Diagnostics Inc Amplification of nucleic acids by replicating a self-sustaining enzymatic sequence
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
CA2081582A1 (en) 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing
DE69329800D1 (de) 1992-04-27 2001-02-01 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
EP2220492B1 (en) * 2007-11-30 2011-08-31 Genentech, Inc. Vegf polymorphisms and anti-angiogenesis therapy
WO2010124265A1 (en) * 2009-04-24 2010-10-28 University Of Southern California Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
US20120100134A1 (en) * 2009-04-24 2012-04-26 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome

Also Published As

Publication number Publication date
NZ620343A (en) 2016-10-28
KR20140064924A (ko) 2014-05-28
AU2012300986A1 (en) 2014-02-13
RU2014110270A (ru) 2015-10-10
ES2589455T3 (es) 2016-11-14
US20140294811A1 (en) 2014-10-02
CN103946395A (zh) 2014-07-23
CA2845386A1 (en) 2013-03-07
BR112014004763A2 (pt) 2017-03-21
EP2751280A1 (en) 2014-07-09
AR087714A1 (es) 2014-04-09
EP3085793A1 (en) 2016-10-26
JP2014526901A (ja) 2014-10-09
SG2014008585A (en) 2014-04-28
EP2751280B1 (en) 2016-06-29
WO2013030168A1 (en) 2013-03-07
ZA201400950B (en) 2015-08-26
IL230783A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
UA115540C2 (uk) Антитіло до il-36r
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MX2021013938A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
EA201590747A1 (ru) Способы лечения с использованием аденовируса
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
EA201391074A1 (ru) Профили экспрессии генов рака толстой кишки и способы применения
MX344315B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
MX2016004557A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX2017015922A (es) Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
EA201291040A1 (ru) Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
AU2012342682A8 (en) Responsiveness to angiogenesis inhibitors
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama